Gross Margin

32%
Current
Improving
by 0.5%
vs 3-y average of 31.5%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
32%
=
Gross Profit
$4.3B
/
Revenue
$13.3B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
32%
=
Gross Profit
€4.3B
/
Revenue
$13.3B

Peer Comparison

Country Company Market Cap Gross
Margin
US
DaVita Inc
NYSE:DVA
7.7B USD
Loading...
US
CVS Health Corp
NYSE:CVS
94.7B USD
Loading...
US
Cigna Corp
NYSE:CI
72.5B USD
Loading...
US
Cigna Group
XMUN:CGN
60.8B EUR
Loading...
DE
Fresenius SE & Co KGaA
XETRA:FRE
27.1B EUR
Loading...
DE
Fresenius Medical Care AG
XMUN:FME
22.2B EUR
Loading...
US
Laboratory Corporation of America Holdings
NYSE:LH
22.5B USD
Loading...
US
Quest Diagnostics Inc
NYSE:DGX
20.5B USD
Loading...
US
Guardant Health Inc
NASDAQ:GH
14B USD
Loading...
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.1B EUR
Loading...
AU
Sonic Healthcare Ltd
ASX:SHL
11B AUD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
34th
Based on 12 729 companies
34th percentile
32%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

DaVita Inc
Glance View

In the intricate network of healthcare services, DaVita Inc. stands as a pivotal player, focusing on the often-overlooked but critical field of kidney care. Rooted in its mission to improve patients' quality of life by innovating kidney care therapies, DaVita has cultivated a robust operation primarily revolving around dialysis services. Chronic Kidney Disease (CKD) and kidney failure are rising global health concerns, necessitating regular dialysis treatments for affected individuals. DaVita serves this need through a network of dialysis centers, offering both in-center and at-home dialysis options. By prioritizing patient comfort and convenience alongside medical efficiency, DaVita has positioned itself as a go-to choice for those requiring ongoing renal care, effectively making the process as seamless as possible for patients. The business model of DaVita hinges on its ability to deliver consistent, high-quality care while managing costs—a balance crucial to success in the healthcare industry. Revenue flows in from both governmental programs such as Medicare and private health insurers, which fund the dialysis treatments for insured patients. DaVita's strategic strength lies in its operational scale, with a vast number of outpatient dialysis centers across the U.S. and internationally. This extensive reach not only strengthens its market position but also provides a wealth of data and feedback, fueling further innovation and efficiency improvements. By leveraging this extensive network, DaVita continues to tap into the growing demand for accessible, comprehensive kidney care services, reinforcing its commitment to patient-centered healthcare delivery while sustaining its financial growth.

TRL Intrinsic Value
232.95 EUR
Undervaluation 61%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
32%
=
Gross Profit
$4.3B
/
Revenue
$13.3B
What is DaVita Inc's current Gross Margin?

The current Gross Margin for DaVita Inc is 32%, which is above its 3-year median of 31.5%.

How has Gross Margin changed over time?

Over the last 3 years, DaVita Inc’s Gross Margin has increased from 29.7% to 32%. During this period, it reached a low of 29.3% on Mar 31, 2023 and a high of 32.9% on Dec 31, 2024.

Back to Top